Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2021

Open Access 01-12-2021 | Lung Cancer | Research

Nuclear Transglutaminase 2 interacts with topoisomerase II⍺ to promote DNA damage repair in lung cancer cells

Authors: Xiao Lei, Kun Cao, Yuanyuan Chen, Hui Shen, Zhe Liu, Hongran Qin, Jianming Cai, Fu Gao, Yanyong Yang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Login to get access

Abstract

Background

To block repairs of DNA damages, especially the DNA double strand break (DSB) repair, can be used to induce cancer cell death. DSB repair depends on a sequential activation of DNA repair factors that may be potentially targeted for clinical cancer therapy. Up to now, many protein components of DSB repair complex remain unclear or poorly characterized. In this study, we discovered that Transglutaminase 2 (TG2) acted as a new component of DSB repair complex.

Methods

A bioinformatic analysis was performed to identify DNA damage relative genes from dataset from The Cancer Genome Atlas. Immunofluorescence and confocal microscopy were used to monitor the protein localization and recruitment kinetics. Furthermore, immunoprecipitation and mass spectrometry analysis were performed to determine protein interaction of both full-length and fragments or mutants in distinct domain. In situ lung cancer model was used to study the effects cancer therapy in vivo.

Results

After DSB induction, cytoplasmic TG2 was extensively mobilized and translocated into nucleus after phosphorylated at T162 site by DNA-PKcs. Nuclear TG2 quickly accumulated at DSB sites and directly interacting with Topoisomerase IIα (TOPOIIα) with its TGase domain to promote DSB repair. TG2 deficient cells lost capacity of DSB repair and become susceptible to ionizing radiation. Specific inhibition of TG2-TOPOIIα interaction by glucosamine also significantly inhibited DSB repair, which increased sensitivity in lung cancer cells and engrafted lung cancers.

Conclusions

These findings elucidate new mechanism of TG2 in DSB repair trough directly interacting with TOPOIIα, inhibition of which provided potential target for overcoming cancer resistance.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Tubbs A, Nussenzweig A. Endogenous DNA Damage as a Source of Genomic Instability in Cancer. Cell. 2017;168(4):644–56.CrossRef Tubbs A, Nussenzweig A. Endogenous DNA Damage as a Source of Genomic Instability in Cancer. Cell. 2017;168(4):644–56.CrossRef
3.
go back to reference Damage DNA. Aging, and Cancer. N Engl J Med. 2009;361(19):1914–4. Damage DNA. Aging, and Cancer. N Engl J Med. 2009;361(19):1914–4.
4.
go back to reference Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer. 2016;16(1):35–42.CrossRef Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer. 2016;16(1):35–42.CrossRef
5.
go back to reference Curtin N. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12(12):801–17.CrossRef Curtin N. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12(12):801–17.CrossRef
6.
go back to reference Bao S, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–60.CrossRef Bao S, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–60.CrossRef
7.
go back to reference Pilié P, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81–104.CrossRef Pilié P, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81–104.CrossRef
8.
go back to reference Panier S, Boulton S. Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol. 2014;15(1):7–18.CrossRef Panier S, Boulton S. Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol. 2014;15(1):7–18.CrossRef
9.
go back to reference Shengxian, et al., An OB-fold complex controls the repair pathways for DNA double-strand breaks. Nature Communications, 2018. Shengxian, et al., An OB-fold complex controls the repair pathways for DNA double-strand breaks. Nature Communications, 2018.
10.
go back to reference Bredemeyer A, et al. ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. Nature. 2006;442(7101):466–70.CrossRef Bredemeyer A, et al. ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. Nature. 2006;442(7101):466–70.CrossRef
11.
go back to reference Ai L, et al. Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor kappa light chain enhancer of activated B cells (NFkappaB) signaling controls basal and DNA damage-induced transglutaminase 2 expression. J Biol Chem. 2012;287(22):18330–41.CrossRef Ai L, et al. Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor kappa light chain enhancer of activated B cells (NFkappaB) signaling controls basal and DNA damage-induced transglutaminase 2 expression. J Biol Chem. 2012;287(22):18330–41.CrossRef
12.
go back to reference Tucholski J. TG2 protects neuroblastoma cells against DNA-damage-induced stress, suppresses p53 activation. Amino Acids. 2010;39(2):523–32.CrossRef Tucholski J. TG2 protects neuroblastoma cells against DNA-damage-induced stress, suppresses p53 activation. Amino Acids. 2010;39(2):523–32.CrossRef
13.
go back to reference Zhang H, et al. TG2 and NF-kappaB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy. Cancer Res. 2016;76(21):6410–23.CrossRef Zhang H, et al. TG2 and NF-kappaB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy. Cancer Res. 2016;76(21):6410–23.CrossRef
14.
go back to reference Yoo J, et al. Transglutaminase 2 promotes both caspase-dependent and caspase-independent apoptotic cell death via the calpain/Bax protein signaling pathway. J Biol Chem. 2012;287(18):14377–88.CrossRef Yoo J, et al. Transglutaminase 2 promotes both caspase-dependent and caspase-independent apoptotic cell death via the calpain/Bax protein signaling pathway. J Biol Chem. 2012;287(18):14377–88.CrossRef
15.
go back to reference Hong G, et al. Inflammatory mediators resulting from transglutaminase 2 expressed in mast cells contribute to the development of Parkinson’s disease in a mouse model. Toxicol Appl Pharmcol. 2018;358:10–22.CrossRef Hong G, et al. Inflammatory mediators resulting from transglutaminase 2 expressed in mast cells contribute to the development of Parkinson’s disease in a mouse model. Toxicol Appl Pharmcol. 2018;358:10–22.CrossRef
16.
go back to reference Wang K, et al. Blocking TG2 attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting EMT. 276: Respiratory physiology & neurobiology; 2020. p. 103402. Wang K, et al. Blocking TG2 attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting EMT. 276: Respiratory physiology & neurobiology; 2020. p. 103402.
17.
go back to reference Kuo T, Tatsukawa H, Kojima S. New insights into the functions and localization of nuclear transglutaminase 2. FEBS J. 2011;278(24):4756–67.CrossRef Kuo T, Tatsukawa H, Kojima S. New insights into the functions and localization of nuclear transglutaminase 2. FEBS J. 2011;278(24):4756–67.CrossRef
18.
go back to reference Li J, Azam F, Zhang S. Outer membrane vesicles containing signalling molecules and active hydrolytic enzymes released by a coral pathogen Vibrio shilonii AK1. Environ Microbiol. 2016;18(11):3850–66.CrossRef Li J, Azam F, Zhang S. Outer membrane vesicles containing signalling molecules and active hydrolytic enzymes released by a coral pathogen Vibrio shilonii AK1. Environ Microbiol. 2016;18(11):3850–66.CrossRef
19.
go back to reference Shen Z, et al. A WD-repeat protein stabilizes ORC binding to chromatin. Molecular cell. 2010;40(1):99–111.CrossRef Shen Z, et al. A WD-repeat protein stabilizes ORC binding to chromatin. Molecular cell. 2010;40(1):99–111.CrossRef
20.
go back to reference Shrestha R, et al., Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells. Cell Death Dis, 2015. 6: p. e2002. Shrestha R, et al., Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells. Cell Death Dis, 2015. 6: p. e2002.
21.
go back to reference Shrestha R, et al., Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells. Cell death & disease, 2015. 6: p. e2002. Shrestha R, et al., Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells. Cell death & disease, 2015. 6: p. e2002.
22.
go back to reference Gundemir S, Johnson GV. Intracellular localization and conformational state of transglutaminase 2: implications for cell death. PLoS One. 2009;4(7):e6123.CrossRef Gundemir S, Johnson GV. Intracellular localization and conformational state of transglutaminase 2: implications for cell death. PLoS One. 2009;4(7):e6123.CrossRef
23.
go back to reference Bruce S, Peters T. The subcellular localization of transglutaminase in normal liver and in glucagon-treated and partial hepatectomized rats. Bioscience reports. 1983;3(12):1085–90.CrossRef Bruce S, Peters T. The subcellular localization of transglutaminase in normal liver and in glucagon-treated and partial hepatectomized rats. Bioscience reports. 1983;3(12):1085–90.CrossRef
24.
go back to reference Zhang B, et al. NBS1 is required for SPO11-linked DNA double-strand break repair in male meiosis. Cell death differentiation. 2020;27(7):2176–90.CrossRef Zhang B, et al. NBS1 is required for SPO11-linked DNA double-strand break repair in male meiosis. Cell death differentiation. 2020;27(7):2176–90.CrossRef
25.
go back to reference Hakem R. DNA-damage repair; the good, the bad, and the ugly. Embo Journal, 2008. 27. Hakem R. DNA-damage repair; the good, the bad, and the ugly. Embo Journal, 2008. 27.
26.
go back to reference Scully R, et al. DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol. 2019;20(11):698–714.CrossRef Scully R, et al. DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol. 2019;20(11):698–714.CrossRef
27.
go back to reference D’Eletto M, et al. Transglutaminase Type 2 Regulates ER-Mitochondria Contact Sites by Interacting with GRP75. Cell reports. 2018;25(13):3573–81.e4.CrossRef D’Eletto M, et al. Transglutaminase Type 2 Regulates ER-Mitochondria Contact Sites by Interacting with GRP75. Cell reports. 2018;25(13):3573–81.e4.CrossRef
28.
go back to reference Hoac B, et al. Mineralization-inhibiting effects of transglutaminase-crosslinked polymeric osteopontin. Bone. 2017;101:37–48.CrossRef Hoac B, et al. Mineralization-inhibiting effects of transglutaminase-crosslinked polymeric osteopontin. Bone. 2017;101:37–48.CrossRef
29.
go back to reference Jung S, et al. Identification of transglutaminase 2 kinase substrates using a novel on-chip activity assay. Biosens Bioelectron. 2016;82:40–8.CrossRef Jung S, et al. Identification of transglutaminase 2 kinase substrates using a novel on-chip activity assay. Biosens Bioelectron. 2016;82:40–8.CrossRef
30.
go back to reference Ayinde O, Wang Z, Griffin M. Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells. Oncotarget. 2017;8(12):20025–41.CrossRef Ayinde O, Wang Z, Griffin M. Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells. Oncotarget. 2017;8(12):20025–41.CrossRef
31.
go back to reference Bagatur Y, et al. Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma. Cell adhesion migration. 2018;12(2):138–51.PubMed Bagatur Y, et al. Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma. Cell adhesion migration. 2018;12(2):138–51.PubMed
32.
go back to reference Lee M, et al. Tissue transglutaminase 2 expression is epigenetically regulated in human lung cancer cells and prevents reactive oxygen species-induced apoptosis. Cancer management research. 2018;10:2835–48.CrossRef Lee M, et al. Tissue transglutaminase 2 expression is epigenetically regulated in human lung cancer cells and prevents reactive oxygen species-induced apoptosis. Cancer management research. 2018;10:2835–48.CrossRef
33.
go back to reference Meshram D, Pike C, Coussons P. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy. Eur J Pharmacol. 2017;815:332–42.CrossRef Meshram D, Pike C, Coussons P. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy. Eur J Pharmacol. 2017;815:332–42.CrossRef
34.
go back to reference Yu C, et al. Tissue transglutaminase 2 exerts a tumor-promoting role in hepatitis B virus-related hepatocellular carcinoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine; 2016.CrossRef Yu C, et al. Tissue transglutaminase 2 exerts a tumor-promoting role in hepatitis B virus-related hepatocellular carcinoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine; 2016.CrossRef
35.
go back to reference Kumar A, et al. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 2012;14(1):R4.CrossRef Kumar A, et al. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 2012;14(1):R4.CrossRef
36.
go back to reference Verma A, Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy, 2007. 10: p. 144–51. Verma A, Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy, 2007. 10: p. 144–51.
37.
go back to reference Cao L, et al. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis. 2008;29(10):1893–900.CrossRef Cao L, et al. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis. 2008;29(10):1893–900.CrossRef
Metadata
Title
Nuclear Transglutaminase 2 interacts with topoisomerase II⍺ to promote DNA damage repair in lung cancer cells
Authors
Xiao Lei
Kun Cao
Yuanyuan Chen
Hui Shen
Zhe Liu
Hongran Qin
Jianming Cai
Fu Gao
Yanyong Yang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-02009-2

Other articles of this Issue 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine